DrugBank ID: db09079
DrugCentral: nintedanib
Synonymous :methyl (3z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1h-indole-6-carboxylate | nintedanib

Drug Sentece Context

Table 1. Analysis of context sentence of nintedanib gene in 4 abstracts.

pmid sentence
32513299 Have used other anti-pulmonary fibrosis drugs in the past 14 days, such as nintedanib, pirfenidone, penicillamine, colchicine, tumor necrosis factor alpha blocker, imatinib, glucocorticoid hormones, morphomycodyl esters, azathioprine, cyclophosphamide, interferon-γ, and traditional Chinese medicine;6.
32894907 Pirfenidone and Nintedanib had been approved for the treatment of idiopathic pulmonary fibrosis(IPF), showing effectiveness on non-IPF pulmonary fibrosis as well.
32992435 Pirfenidone and Nintedanib are encouraged to apply on patients in reparative phase with evidence of progressing fibrosis.
33107641 Finally, we suggested the therapeutic value of two drugs (pirfenidone and nintedanib) for idiopathic pulmonary fibrosis in COVID-19-induced pulmonary fibrosis.
33378971 Nintedanib and pirfenidone are the only two known drugs which are conditionally recommended for the treatment of IPF by the FDA.
33396592 Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. […] Nintedanib is used in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases and lung cancer. […] The mechanism of action suggests that nintedanib should be considered one of the potential agents for inhibiting and revising the fibrosis process related to COVID-19 infections. […] Due to the known induction of coagulation pathways during COVID-19 infections, possible interaction between nintedanib and anticoagulant seems to be an extremely important issue. […] In theory, nintedanib could increase the bleeding risk, thrombosis and lead to thrombocytopenia. […] The data from clinical trials on the concomitant use of nintedanib and antithrombotic agents is very limited as this patient group was within the standard exclusion criteria. […] Nintedanib is an important therapeutic option, despite its interaction with anticoagulants. […] If anticoagulant therapy is necessary, the more effective and safer option is the concomitant administration of DOACs and nintedanib, especially when drug-monitored therapy will be used in patients at high risk of bleeding complications.